These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36841507)

  • 21. Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy.
    Diestelhorst M; Nordmann JP; Toris CB
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S155-61. PubMed ID: 12204713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
    Fuwa M; Ueda K; Akaishi T; Yamashita N; Kirihara T; Shimazaki A; Mano H; Kawazu K
    PLoS One; 2016; 11(7):e0158797. PubMed ID: 27383260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination.
    Inoue K; Okayama R; Higa R; Sawada H; Wakakura M; Tomita G
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):581-7. PubMed ID: 22011049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of latanoprost in eyes with uveitic glaucoma.
    Markomichelakis NN; Kostakou A; Halkiadakis I; Chalkidou S; Papakonstantinou D; Georgopoulos G
    Graefes Arch Clin Exp Ophthalmol; 2009 Jun; 247(6):775-80. PubMed ID: 19184081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.
    Diestelhorst M; Larsson LI;
    Br J Ophthalmol; 2004 Feb; 88(2):199-203. PubMed ID: 14736774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pneumatic trabeculoplasty vs latanoprost as adjunctive therapy to timolol in primary open-angle glaucoma or ocular hypertension.
    Uva MG; Longo A; Reibaldi M
    Graefes Arch Clin Exp Ophthalmol; 2009 Aug; 247(8):1103-9. PubMed ID: 19247684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension.
    Zhang WY; Po AL; Dua HS; Azuara-Blanco A
    Br J Ophthalmol; 2001 Aug; 85(8):983-90. PubMed ID: 11466259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma.
    Camras CB; Hedman K;
    J Glaucoma; 2003 Dec; 12(6):466-9. PubMed ID: 14646680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
    Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
    Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension.
    Feldman RM
    Expert Opin Pharmacother; 2004 Apr; 5(4):909-21. PubMed ID: 15102573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma.
    Parmaksiz S; Yüksel N; Karabas VL; Ozkan B; Demirci G; Caglar Y
    Eur J Ophthalmol; 2006; 16(1):73-80. PubMed ID: 16496249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Four years later: a clinical update on latanoprost.
    Ravinet E; Mermoud A; Brignoli R
    Eur J Ophthalmol; 2003 Mar; 13(2):162-75. PubMed ID: 12696636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment.
    Cheng YH; Tsai TH; Jhan YY; Chiu AW; Tsai KL; Chien CS; Chiou SH; Liu CJ
    Carbohydr Polym; 2016 Jun; 144():390-9. PubMed ID: 27083831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study.
    Emmerich KH
    Graefes Arch Clin Exp Ophthalmol; 2000 Jan; 238(1):19-23. PubMed ID: 10664047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study.
    Chiseliţă D; Antohi I; Medvichi R; Danielescu C
    Oftalmologia; 2005; 49(3):39-45. PubMed ID: 16408674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma.
    Gupta SK; Agarwal R; Galpalli ND; Srivastava S; Agrawal SS; Saxena R
    Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):665-71. PubMed ID: 18200329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
    Facio AC; Reis AS; Vidal KS; de Moraes CG; Suzuki R; Hatanaka M; Susanna R
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):447-51. PubMed ID: 19860553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Xalacom: possibilities and advantages of the drug in the treatment of patients with glaucoma].
    Alekseev IB; Volkova AV; Alekseeva LI
    Vestn Oftalmol; 2022; 138(5):119-125. PubMed ID: 36288426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination.
    Sellem E; Rouland JF; Baudouin C; Bron A; Denis P; Nordmann JP; Renard JP
    BMC Ophthalmol; 2010 Mar; 10():10. PubMed ID: 20346127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.